Go Party? Go Skafa! Go Skafa! Go Party!

Office of the U.S. Trade Representative. Agreement between the United States of America, the United States of Mexico and Canada. ustr.gov/trade-agreements/free-trade-agreements/united-states-mexico-canada-agreement/agreement-between. Access 14 Dec 2018. Gleeson D, Menkes DM. Commercial agreement and direct drug advertising. Int J Manag Public Health Policy. 2018;7(2):98–100.

The legal texts open to the public in the agreements, including annexes and ancillary instruments, are derived from government websites (mainly the New Zealand Department of Foreign Affairs and Trade, World Affairs Canada and Office of the United States Trade Representative). Footnote 5 The contents of all drug-related texts have been scanned to identify relevant provisions; The relevant chapters, annexes and ancillary instruments were then selected for further review. The selection process was conducted independently of the lead author and the second author, and the discrepancies were resolved through discussion. provisions with potential effects on drugs were categorized according to their effects on pharmaceutical policy; agreements and significant differences. Footnote 6 The relevant chapters, appendices and ancillary instruments for each category were independently analyzed by the lead author and another member of the research team, and the discrepancies were resolved by the discussion. In order to establish the analytical framework, the comparison of the texts of the four agreements focused on identifying provisions that could have new or progressive implications for pharmaceutical policy compared to other agreements. Significant trend reversals were also observed. B (for example, the suspension of certain provisions of the CPTPP). Another provision in Chapter 8 of the TPP, contained in Chapter 11 of the USMCA, requires members to „allow individuals of another party to participate in the development of technical rules, standards and procedures for assessing compliance by their governing bodies on conditions that are no less favourable than those accorded to their own persons“ (TPP.

8.7.1; Article 11.7.1 of USMCA ARTICLE 11.7.1. A footnote to each agreement allows the parties to limit this obligation to „give interested parties an appropriate opportunity to comment on the extent proposed“ and to „take these observations into account in the evolution of the measure.“ The USMCA goes even further, with a provision requiring contracting parties to allow „persons of another party“ to participate in groups or committees that develop standards, on „no less favourable terms than their own persons“ (Article 11.7.8). These provisions could enable pharmaceutical industry stakeholders to influence drug decision-making in other countries. The IP provisions contained in these agreements may delay the entry into the market of cheaper generic drugs and biosimilars, this allows high prices to be maintained over a long period of time, affecting public spending on medicines and/or consumer wallets, depending on the health system of each country [1,2,3,4,5,6,7,8, 29]. Footnote 8 They can also „imprison“ a high level of intellectual property protection in order to prevent or limit reforms, since the revision of trade agreements generally requires the agreement of all contracting parties.

Comments are closed.